Risky Osteoporosis Drug may be Suspended

An osteoporosis drug, apparently risky, including the risk of heart attacks, may now be suspended by a committee in Europe

An osteoporosis drug, apparently risky, including the risk of heart attacks, may now be suspended by a committee in Europe.

The drug, Protelos/Osseor, is prescribed for people with the bone-crumbling disease who often suffer debilitating fractures.

Research may Explain Fractures in Some Who Take Osteoporosis Drugs
At the Texas Biomedical Research Institute, research with baboons may help explain why some people who take bone-strengthening drugs like bisphosphonates are at-risk for atypical fractures in the long bones in their legs.

A product of French firm Servier Laboratories, the medicine is said to make bones stronger and prevent breaks.

But the PRAC risk assessment committee of the European Medicines Agency (EMA) said the risks of serious heart problems, including heart attacks, blood clots and blocked arteries, were just too great.

For every 1,000 treated patients, there were four additional cases of serious heart problems and four of clotting among people using Protelos/Osseor compared to those given a placebo or dummy treatment.

In Murine Osteoporosis, Choloroquine Reduces Formation of Bone Resorbing Cells
Bone homeostasis requires precise balance between resorption of old bone by osteoclasts and deposition of new bone by osteoblasts.

Other risks include seizures and liver inflammation.

As an osteoporosis treatment, the drug has shown a "modest effect" -- preventing about five non-spinal bone fractures, 15 spinal fractures and 0.4 hip fractures per 1,000 patients, the committee said.

Novel Osteoporosis Drug Romosozumab Shows Promise in Strengthening Bone
Researchers are reporting that a new osteoporosis drug induces the body to rebuild bone and could potentially change the way osteoporosis is treated.

"The PRAC weighed the benefits of the medicine against the known risks and concluded that the balance was no longer favourable, and recommended Protelos/Osseor be suspended until there are new data showing a favourable balance in a defined patient group," a statement said.

The recommendation will next be considered by the EMA's Committee for Medicinal Products for Human Use for a final decision.

Servier in a statement informed national health agencies of Friday's announcement, and said it would provide further information once the EMA review is concluded.

Source-AFP